Neuroscience

#CAR-T #Cell therapy #Immunotherapy #Neurodegenerative disorders #Neuroscience #Oncology

This week in drug discovery (16-20 September) 

News round-up for 16-20 September by DDW Senior Digital Content Editor Diana Spencer. This week we have seen a number of developments related to cell therapies, particularly CAR-T cell therapies, beyond their traditional use in haematological malignancies. The top stories: Study shows low… Read More

#News

#ALS #Brain #Dementia #Neurodegenerative disorders #Neuroscience

New DDW Highlights podcast: 17 September 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. This week, DDW has opened registrations for its webinar ‘The latest… Read More

#News

#ALS #Brain #Dementia #Neurodegenerative disorders #Neuroscience

New DDW Highlights vodcast: 17 September 2024

Every week, DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates in the DDW Highlights podcast. It is now also available in a concise vodcast format.   This week, DDW has opened… Read More

#News

#Amyotrophic lateral sclerosis (ALS) #CNS #Drug development #Drug discovery #Neuroscience #Webinar

Webinar on driving neuroscience drug discovery research

In this webinar on 30 September, from 3-4PM BST, hosted by DDW and sponsored by ApconiX, you will hear from Dr Isaac Klein, Chief Scientific Officer at Dewpoint Therapeutics, Dr Sam Clark, CEO of Terran Biosciences, and Professor Ruth Roberts, Co-founder and Director of Safety Science at ApconiX. Read More

#News

#ALS #Brain #Dementia #Neurodegenerative disorders #Neuroscience

This week in drug discovery (9-13 September) 

News round-up for 9-13 September by DDW Senior Digital Content Editor Diana Spencer. This week, DDW has opened registrations for its webinar ‘The latest advancements driving neuroscience drug discovery research’, so our news highlights focus on developments in neuroscience, including a novel drug that has… Read More

#News

Neurons
#Aberdeen University #Durham University #Neurodegenerative disorders #Neuroscience #Nevrargenics #Preclinical investigations

Novel drug reduces neuronal death in neurodegenerative disease

New research has shown that Ellorarxine, a novel drug compound developed by biotech Nevrargenics, provides a robust neuroprotective effect and reduces neuronal death in cell models of neurodegenerative disease. The peer reviewed study published in Frontiers in Neuroscience was conducted by academics at Aberdeen and… Read More

#News

#Automata #Automation #Collaboration #Jan and Dan Duncan Neurological Research Institute (Duncan NRI) #Neuroscience #Texas Children's Hospital

Industry/research collaboration to automate human brain studies 

The Jan and Dan Duncan Neurological Research Institute (Duncan NRI) at Texas Children’s Hospital, a neuroscience research institute based in Houston, has advanced its research capabilities with the implementation of an automation platform for human cellular model generation, maintenance, and characterisation, in collaboration with Automata Technologies.   As a global leader… Read More

#Business & Investment #News

#Amyotrophic lateral sclerosis (ALS) #CNS #Drug development #Drug discovery #Neuroscience #Webinar

The latest advancements driving neuroscience drug discovery

In this webinar on 30 September, from 3-4PM BST, hosted by DDW and sponsored by ApconiX, you will hear from Dr Isaac Klein, Chief Scientific Officer at Dewpoint Therapeutics, Dr Sam Clark, CEO of Terran Biosciences, and Professor Ruth Roberts, Co-founder and Director of Safety Science at ApconiX. Read More

#News

Brain physiology
#AGuIX #Cancer research #Clinical trial #Dana-Farber Cancer Institute #Drug discovery #Neuroscience

Phase II brain metastases trial advances after futility analysis 

The Phase II NANOBRAINMETS trial of AGuIX has been validated by the Data Safety and Monitoring Board (DSMB) following a futility analysis scheduled after the enrolment and follow-up of 50% of patients in the study.  The trial is being run by NH TherAguix, a biotechnology company developing… Read More

#Cancer Research #News

Neurons in the brain
#Neurocrine Biosciences #Neuroscience #Phase II trial #Psychiatry #Schizophrenia

Muscarinic M4 selective agonist shows promise in schizophrenia

Neurocrine Biosciences has revealed positive top-line data for its Phase II clinical study of NBI-1117568 (NBI-‘568) in adults with schizophrenia. NBI-‘568 is the first investigational, oral, muscarinic M4 selective agonist in development for this indication. The NBI-‘568-SCZ2028 dose-finding study met its primary endpoint for… Read More

#News

World Parkinson's Day
#Charity #Funding #Neurodegenerative disorders #Neuroscience #Parkinson's

Parkinson’s researchers receive nearly $3 million in grant funding

The US Parkinson’s Foundation has invested nearly $3 million for 33 grants to accelerate Parkinson’s disease (PD) research. The research grants will fund scientists conducting studies across various aspects of PD to bring forward new therapies, treatments, and ultimately a cure for the disease. Read More

#News

Brain inflammation
#Cell culture #Drug discovery #High throughput screening #In vitro #Neuroscience

Balancing in vitro models of neuroinflammation

Dr Gareth Edwards, Senior Bioassay Scientist at Cellomatics Biosciences, explores how modern techniques and high-throughput screening can enhance workflows in neuroinflammation.  Inflammation occurs when specific stimuli induce phenotypic changes by activating signalling cascades that amplify downstream responses. It plays vital roles in both disease progression and tissue repair; in other words,… Read More

#Exclusive Content

#Antidepressants #Neurology #Neuropsychiatric disorders #Neuroscience #Psychedelics #Psychiatry

Reshaping neuropsychiatry

Dr Anantha Shekhar, MD PhD, Dean of the University of Pittsburgh School of Medicine, explores synapse structure and function in neuroscience and how neuroplasticity can present new opportunities for drug development. With contributions from Rob Houghtaling, MS and John Donello, PhD, Gate Neurosciences. In March 2019, the US FDA approved… Read More

#Exclusive Content

Neurons in the brain
#Centogene #Drug targets #Genetics #Neuroscience #Parkinson's

15% of Parkinson’s cases linked to genetic factors, study says 

Centogene has announced data from its Rostock International Parkinson’s Disease (ROPAD) Study revealing the genetic factors and prevalence of Parkinson’s disease (PD).   The findings from the study indicate that approximately 15% of PD-related cases are tied to genetic variants, with the majority being linked to LRRK2 and… Read More

#News

#Brain disease #Johnson & Johnson #Neurology #Neuroscience

Shaping the future of neuroscience

Berkin Gökbudak, Senior Director of Commercial Strategy for Neuroscience, Pulmonary Hypertension & Cardiovascular & Metabolism, at Johnson & Johnson, looks towards neuroscience strategies that can help advance treatments for brain disorders. The human brain is the last, and greatest, scientific frontier – it’s been described as the most complex structure… Read More

#Exclusive Content

#Amyotrophic lateral sclerosis (ALS) #Dementia #epilepsy #Neurodegenerative disorders #Neurology #Neuroscience #Parkinson's

New DDW Highlights podcast: 29 July 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. There have been some interesting developments in neuroscience this week. Perhaps most note-worthy,… Read More

#News